Filing Analysis
NeuroOne Medical Technologies Corp has filed an updated Prospectus Supplement to its existing 'at the market' (ATM) offering program. The company intends to sell up to $13.4 million of its common stock through JonesTrading Institutional Services LLC.
🚩 Red Flags
- Potential for significant shareholder dilution given the $13.4 million offering size relative to typical micro-cap market caps.
📋 Key Facts
- The company is utilizing a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC.
- The updated Prospectus Supplement was filed on June 12, 2026.
- The total amount of shares to be offered under this updated supplement is up to $13.4 million.
- The offering is conducted as an 'at the market' (ATM) offering pursuant to Rule 415(a)(4) of the Securities Act of 1933.
NeuroOne Medical Technologies Corporation (NMTC) disclosed on May 21, 2026 that its Audit Committee determined the interim financial statements in its 10-Q for the quarter ended March 31, 2026 (filed May 12, 2026) must be restated due to revenue recognition errors. The errors stemmed from inadequate internal controls over customer-modified purchase orders, resulting in overstated revenue of ~$529K and overstated gross profit of ~$296K. The company intends to file an amended 10-Q as soon as practicable.
🚩 Red Flags
- Revenue recognition restatement signals weak internal controls over order-to-cash processes, particularly for customer-modified purchase orders
- Multiple 8-K items filed simultaneously (4.02 + 7.01), indicating broader disclosure obligations triggered
- Restatement affects both Q3 FY2026 and the six-month YTD period, widening the scope of unreliable financials
- Preliminary estimates subject to further revision — final restatement impact could be larger than disclosed
- Internal control deficiency (inadequate design and implementation) may indicate a material weakness requiring disclosure in forthcoming amended 10-Q
- Small-cap company (~micro-cap NMTC) restatements often face heightened investor scrutiny and potential Nasdaq compliance concerns
- Only ~10 days elapsed between original 10-Q filing (May 12) and non-reliance determination (May 21), suggesting the error was caught quickly but also raises questions about QC processes
📋 Key Facts
- Audit Committee determination date: May 21, 2026
- Affected filing: 10-Q for quarter ended March 31, 2026, originally filed May 12, 2026
- Revenue and accounts receivable overstated by ~$529 thousand for both the three-month and six-month periods ended March 31, 2026
- Gross profit overstated by ~$296 thousand for both the three-month and six-month periods ended March 31, 2026
- Operating loss and net loss understated by ~$296 thousand for both periods
- Total assets overstated by ~$296 thousand as of March 31, 2026
- Inventory understated by ~$233 thousand as of March 31, 2026
- Root cause: inadequate design and implementation of internal controls over customer-modified purchase orders
- No intentional misconduct identified by management or employees
- Independent auditor: Baker Tilly US, LLP has been consulted
- Restatement figures are preliminary and subject to further changes
- Filing also includes Item 7.01 Regulation FD disclosure via press release dated May 22, 2026
- CEO David Rosa signed the 8-K on May 22, 2026
NeuroOne Medical Technologies Corp announced its financial results for the fiscal quarter ended March 31, 2026. The disclosure was made via a press release furnished under Item 2.02 of the 8-K filing.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended March 31, 2026.
- The press release was issued on May 12, 2026.
- The information was furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
NeuroOne Medical Technologies has regained compliance with Nasdaq's $1.00 minimum bid price requirement. The company had been under a deficiency notice since May 6, 2025, and successfully closed the matter by maintaining a bid price above $1.00 for 10 consecutive business days.
🚩 Red Flags
- The company was in non-compliance for nearly a full year (May 2025 to April 2026), indicating a long period of share price underperformance.
📋 Key Facts
- The company received a deficiency letter from Nasdaq on May 6, 2025, regarding the $1.00 minimum bid price rule.
- On April 30, 2026, Nasdaq notified the company that it had regained compliance.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days.
- The matter is now considered closed by Nasdaq Listing Qualifications Department.
NeuroOne Medical Technologies announced the retirement of CFO Ronald McClurg, effective June 30, 2026. He will be succeeded by the current COO, Christopher Volker, on July 1, 2026, with McClurg remaining as a Senior Advisor through the end of the year to ensure a smooth transition.
📋 Key Facts
- CFO Ronald McClurg to retire effective June 30, 2026.
- Current COO Christopher Volker will assume the CFO role on July 1, 2026.
- Christopher Volker's base salary will increase to $350,000 upon appointment.
- McClurg will remain as a Senior Advisor until December 31, 2026.
- The successor, Christopher Volker, holds a Wharton MBA and a CFA designation, with prior experience at Abbott and St. Jude Medical.
NeuroOne Medical Technologies Corp has announced a 1-for-6 reverse stock split of its common stock, effective April 15, 2026. The action is primarily intended to increase the per-share bid price to regain compliance with Nasdaq's minimum bid price requirements.
🚩 Red Flags
- Reverse stock split (1-for-6 ratio) typically indicates a struggle to maintain the $1.00 Nasdaq minimum bid price.
- The filing explicitly mentions the need to 'regain compliance with the minimum bid price requirement for continued listing'.
📋 Key Facts
- The reverse stock split ratio is 1-for-6.
- The split becomes effective at 5:00 p.m. Eastern Time on April 15, 2026.
- Trading on a split-adjusted basis will commence on the Nasdaq Capital Market on April 16, 2026.
- No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment.
- The number of authorized shares and the par value of the common stock remain unchanged.
- A new CUSIP number (64130M308) has been assigned to the common stock.
NeuroOne Medical Technologies stockholders approved a reverse stock split with a ratio between 1-for-2 and 1-for-15 and authorized an amendment to the 2025 Equity Incentive Plan. The plan amendment increases the share pool by 1.5 million shares and adds a 5% annual evergreen provision through 2031.
🚩 Red Flags
- Approval of a reverse stock split, typically indicative of a need to maintain Nasdaq's minimum bid price requirement.
- Significant potential for shareholder dilution via the 1.5 million share increase and the 5% annual evergreen provision.
📋 Key Facts
- Stockholders approved a reverse stock split at a ratio range of 1-for-2 to 1-for-15, to be determined by the Board.
- The 2025 Equity Incentive Plan was amended to increase the share reserve by 1,500,000 shares.
- An 'evergreen' provision was approved to automatically increase the equity plan shares by 5% of fully diluted shares annually from 2027 to 2031.
- Baker Tilly US, LLP was ratified as the independent auditor for the fiscal year ending September 30, 2026.
- Approximately 59.72% of outstanding shares were represented at the Annual Meeting held on April 3, 2026.
NeuroOne Medical Technologies Corp has scheduled its 2026 Annual Meeting of Stockholders for April 3, 2026. Because this date is more than 30 days from the anniversary of the 2025 meeting, the company has set a new deadline of March 4, 2026, for stockholder proposals.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is scheduled for April 3, 2026.
- The deadline for receipt of stockholder proposals under Rule 14a-8 is March 4, 2026.
- The meeting date change exceeds 30 calendar days from the anniversary of the 2025 annual meeting.